Evolution of FXI(a) as a target for antithrombotic therapy

27 August 2023 (10:30 - 10:40)

Organised by:

About the speaker

Doctor Jeffrey Weitz

Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton (Canada)

5 More presentations in this session

Presentation thumbnail

Welcome and introduction

Professor M. Sharma (Hamilton, CA)

Presentation thumbnail

Epidemiology of stroke and disease burden

Professor M. Blomstrom-Lundqvist (Orebro, SE)

Presentation thumbnail

Uncovering the unmet need for patients: - with atrial fibrillation at risk of stroke - acute non-cardioembolic ischemic stroke or high-risk TIA

Professor M. Blomstrom-Lundqvist (Orebro, SE) Professor M. Sharma (Hamilton, CA)

Presentation thumbnail

Outlining the clinical evidence landscape for FXI(a) inhibition: - stroke and bleeding prevention for patients with AF at risk of stroke - secondary stroke prevention in acute non-cardioembolic ischemic stroke or high-risk TIA

Professor J. De Groot (Amsterdam, NL) Professor M. Sharma (Hamilton, CA)

Presentation thumbnail

Q&A and closing remarks

Access the full session

Session thumbnail

How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?

The Event

Event poster

ESC Congress 2023

27 August 2023 10:30 CET

You may be interested in

Congress Presentation

Factor XI inhibition uncoupled: mechanistic insights and rationale

30 August 2024

Webinar

Cancer associated thrombosis: have DOACs changed daily practice?

21 September 2021

Congress Presentation

Factor XI inhibitors or direct oral anticoagulants in atrial fibrillation: an updated meta-analysis

1 September 2025

Webinar

Are NOACs already outdated? New trends in anticoagulation therapy

12 December 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources